What Happened?

Shares of life sciences company Bio-Techne (NASDAQ: TECH) jumped 4.6% in the afternoon session after the investment firm Stephens initiated coverage on the stock with an "overweight" rating and a $65.00 price target. 

An "overweight" rating suggests that the analyst believes the stock will perform better than the overall market or its sector in the near future. The price target of $65.00 represented a potential upside of nearly 24% from the stock's previous closing price, signaling strong conviction from the new analyst. This positive initiation comes after several other analysts had previously set "hold" ratings on the life sciences company. The new bullish coverage from Stephens may have prompted investors to reconsider the stock's growth prospects, leading to the sharp upward move in the share price.

After the initial pop the shares cooled down to $52.49, up 4.4% from previous close.

Is now the time to buy Bio-Techne? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Bio-Techne’s shares are somewhat volatile and have had 14 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The biggest move we wrote about over the last year was 2 months ago when the stock gained 7.8% after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains. 

However, President Trump clarified that tariffs could go "substantially higher" if a full deal with China wasn't reached during the 90-day pause, but not all the way back to the previous levels. Still, the agreement has cooled fears of a prolonged trade war, helping stabilize expectations for global growth and trade flows and fueling renewed optimism. The optimism appeared concentrated in key trade-sensitive sectors, particularly technology, retail, and industrials, as lower tariffs reduce cost pressures and restore cross-border demand.

Bio-Techne is down 26.6% since the beginning of the year, and at $52.49 per share, it is trading 36.3% below its 52-week high of $82.35 from July 2024. Investors who bought $1,000 worth of Bio-Techne’s shares 5 years ago would now be looking at an investment worth $760.85.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.